

SAFETY DATA SHEET



GlaxoSmithKline

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Material	NIMBEX
Synonyms	NIMBEX FORTE * NIMBEX INJECTION 2 MG/ML * NIMBEX INJECTION 5 MG/ML * NIMBEX INJECTION 10 MG/ML * CIS-ATRACURIUM BESYLATE, FORMULATED PRODUCT
Company Name	<p>GlaxoSmithKline, Corporate Environment, Health & Safety 980 Great West Road Brentford, Middlesex TW8 9GS UK</p> <p>UK General Information: +44-20-8047-5000 Transport Emergency (EU) +44-1865-407333 Medical Emergency +1-612-221-3999, Ext 221 Information and Advice: US number, available 24 hours Multi-language response</p> <p>GlaxoSmithKline, Corporate Environment, Health & Safety 2200 Renaissance Blvd, Suite 105 King of Prussia, PA 19406 US</p> <p>US General Information: +1-888-825-5249 Transport Emergency (non EU) +1-703-527-3887 US number, available 24 hours Multi-language response</p>

2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS RN	Percentage
CIS-ATRACURIUM BESYLATE	96946-42-8	0.2 to 1.05
NON-HAZARDOUS INGREDIENTS	Unassigned	98.95 to 99.8

3. HAZARDS IDENTIFICATION

Fire and Explosion	This product is classified as non-flammable.
Health	<p>Caution - Potent pharmaceutical agent. Pharmacological effects may occur following skin absorption. Possible effects of overexposure in the workplace include: symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing); paralysis; respiratory depression; increased heart rate; bronchospasm; decrease in blood pressure; flushing. Exposure might occur via ingestion; skin; eyes. Health effects information is based on hazards of components. Handling this product in its final form presents minimal risk from occupational exposure.</p>

Environment	No information is available about the potential of this product to produce adverse environmental effects.
--------------------	---

4. FIRST-AID MEASURES

Ingestion	Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.
Inhalation	Physical form suggests that risk of inhalation exposure is negligible.
Skin Contact	Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.
Eye Contact	Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment	Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre. Medical treatment in cases of overexposure should be treated as an overdose of neuromuscular blocking agent.
Medical Conditions Caused or Aggravated by Exposure	Refer to prescribing information for detailed description of medical conditions caused by or aggravated by overexposure to this product.
Health Surveillance Procedures	Pre-placement and periodic health surveillance is not usually indicated. The final determination of the need for health surveillance should be determined by local risk assessment.
Antidotes	No specific antidotes are recommended.

5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards	Not expected for the product, although the packaging is combustible.
Extinguishing Media	No special requirements needed.
Special Firefighting Procedures	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal.
Hazardous Combustion Products	Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions	Wear protective clothing and equipment consistent with the degree of hazard.
Environmental Precautions	For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.
Clean-up Methods	Collect and place it in a suitable, properly labelled container for recovery or disposal.
Decontamination Procedures	No specific decontamination or detoxification procedures have been identified for this product.

7. HANDLING AND STORAGE

HANDLING

General Requirements No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.

STORAGE

No storage requirements necessary for occupational hazards. Follow product information storage instructions to maintain efficacy.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

INGREDIENT CIS-ATRACURIUM BESYLATE

GSK Occupational Hazard Category 3

GSK Occupational Exposure Limit 35 mcg/m³ (15 MIN STEL)

ENGINEERING CONTROLS

Exposure Controls An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. Refer to the Exposure Control Matrix for more information about how ECA's are assigned and how to interpret them.

PERSONAL PROTECTIVE EQUIPMENT

Eye Protection Wear approved safety glasses with side shields if eye contact is possible.

Other Equipment or Procedures Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling. An eye wash station should be available.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Physical Form Liquid.

pH of Aqueous Solutions 3.3 to 3.8

10. STABILITY AND REACTIVITY

Stability This product is expected to be stable.

Conditions to Avoid None for normal handling of this product.

11. TOXICOLOGICAL INFORMATION

Oral Toxicity Not expected to be toxic following ingestion.

Skin Effects Irritation is not expected following direct contact. Pharmacological effects may occur following skin absorption.

Eye Effects Irritation is not expected following direct contact with eyes. Direct contact with eyes might produce evidence of pharmacological effects.

Target Organ Effects No specific target organ effects have been identified.

Sensitisation Sensitisation (allergic skin reaction) is not expected.

Genetic Toxicity Not expected to be genotoxic under occupational exposure conditions.

Carcinogenicity No components are listed as carcinogens by GSK, IARC, NTP or US OSHA.

Reproductive Effects	Not expected to produce adverse effects on fertility or development under occupational exposure conditions.
Pharmacological Effects	This material is a muscle relaxant for use during anaesthesia. Adverse effects of overexposure might include: symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing); paralysis; respiratory depression; decrease in blood pressure; bronchospasm; flushing.
Other Adverse Effects	None known for this material in humans.

12. ECOLOGICAL INFORMATION

Summary	No information is available about the potential of this product to produce adverse environmental effects. This material contains an active pharmaceutical ingredient that has had limited testing and no adverse environmental effects were observed in the tests conducted. Local regulations and procedures should be consulted prior to environmental release.
----------------	---

13. DISPOSAL CONSIDERATIONS

Disposal Recommendations	Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.
Regulatory Requirements	Observe all local and national regulations when disposing of this product.

14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

UN Classification and Labelling

Transport Information	Transportation and shipping of this product is not restricted. It has no known, significant hazards requiring special packaging or labelling for air, maritime, US or European ground transport purposes.
------------------------------	---

15. REGULATORY INFORMATION

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

EU Classification and Labelling

None.

US OSHA Standard (29 CFR Part 1910.1200)

Classification	This product is classified as hazardous according to the OSHA Hazard Communication Standard.
-----------------------	--

Other US Regulations

TSCA Status	Exempt
--------------------	--------

16. OTHER INFORMATION

References	GSK Hazard Determination
-------------------	--------------------------

Date Approved/Revised 16-Aug-2003

SDS Version Number 4

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.